Meridian BioSciences

Needs attention

Clinical-stage biotech developing an oral therapy for chronic inflammatory disease, currently in Phase II.

BiotechSeries CSwitzerlandInvested Dec 3, 2019Lead: Jerry

Next board meeting

Tue, August 25

in 4 weeks

Status rationale: A competing therapy received fast-track designation, and the Phase II timeline slipped a quarter on recruitment.Updated Jul 27, 2026

The board pack summary will appear here

Page-level summaries already exist and are readable in the pack viewer. A pack-level summary (executive summary, material changes, key decisions, risks and asks) is not built yet.